Liposome Drug Delivery Market Outlook:
Liposome Drug Delivery Market size was valued at USD 5.88 billion in 2025 and is set to exceed USD 13.54 billion by 2035, expanding at over 8.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of liposome drug delivery is estimated at USD 6.34 billion.
According to the WHO 2021, non-communicable diseases (NCDs) killed no less than 43 million people in the same year which corresponds to 75% of non-pandemic-related deaths globally.18 million people out of that were aged below 70 years, 82% of which were from the low- and middle-income countries. Cardiovascular diseases accounted for 19 million NCD deaths, followed by 10 million deaths caused by cancer, 4 million by chronic respiratory diseases, and 2 million deaths due to diabetes. This rising prevalence of NCDs is driving the demand for liposomal drug delivery due to its ability to enhance drug effectiveness and reduce side effects.
Increasing advances in liposomal drug delivery methods owing to new investments and ongoing R&D activities, are driving the growth of the liposome drug delivery market further. For instance, in August 2024, Lupin Limited launched Doxorubicin Hydrochloride Liposome Injections 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials in the U.S., after receiving approval for its ANDA from the FDA. Moreover, various government authorities have been seen offering funds and investments for the research and development activities of the liposome drug delivery market.
